Noveris Health Sciences Inc.

OTC: MYCOF · Healthcare · Medical - Pharmaceuticals

Canadian filerHQ Vancouver, BCReports USD

#1143 of 1,394 Healthcare companies by revenue

EA Score

——

FH 45DQ —GM —SS 32

v0.1 · 35/100 weight · pillars only

↑ return on assets, Piotroski F · ↓ balance-sheet leverage, workforce scale

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

$2.1M

Employees

Market cap

$117.1M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$00 CAD2025

Net income$2.1M2.9M CAD2025

Operating income-$393.4k-549.9k CAD2025

Total assets$7.1k9.7k CAD2025

Liabilities$9.1M12.5M CAD2025

Equity-$9.1M-12.5M CAD2025

Revenue trend

FY2018 – FY2025 · USD

$160.3k

FY18

$94.6k

FY19

$2.0k

FY20

$6.0k

FY21

FY22

FY23

FY24

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Noveris Health Sciences Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a Infinity% net margin.

Peers · Healthcare

BioSyent Inc.83B+OptimizeRx Corp.72B Corbus Pharmaceuticals Holdings, Inc.44D Black Diamond Therapeutics, Inc.60C

Key facts

CEOJason Birmingham

SectorHealthcare

IndustryMedical - Pharmaceuticals

HeadquartersVancouver, BC

ExchangeOTC: MYCOF

Employees3

IPO date2021-01-08

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.